Abstract

Purpose: Anxiety is a comorbidity that is not routinely addressed in patients with chronic obstructive lung disease (COPD) exacerbation in the emergency department (ED). Anxiety in patients with COPD exacerbation can be related with negative outcomes. The Generalized Anxiety Disorder 7 (GAD-7) score is an easy-to-use tool to determine anxiety. This study aimed to investigate the relationship between GAD-7 score and patient outcomes in patients with COPD exacerbation in the ED.

Methods: A prospective, cross-sectional study was conducted in a tertiary academic ED between July 2019 and January 2021. Patients admitted to the ED with COPD exacerbation were included. A GAD-7 score of ≥10 was defined as clinically significant anxiety. Negative outcomes were defined as a composite outcome that included recurrent ED visits, intensive care unit admission, and mortality. The relationship between clinically significant anxiety and negative outcomes within 30 days was determined.

Results: A total of 92 patients were assessed for eligibility and 80 were included in the study. Thirty-seven patients (46.3%) experienced negative outcomes. Although no significant difference was detected in median GAD-7 scores between patients with positive and negative outcomes, negative outcomes were significantly higher in patients who had a GAD-7 score of ≥10 \((n = 25, p = 0.03)\). A sensitivity of 43.2%, specificity of 79.1%, positive likelihood ratio of 2.1 and negative likelihood ratio of 0.7 were determined for GAD-7 score in predicting negative outcome.

Conclusion: In patients with COPD exacerbation in the ED, a GAD-7 score of ≥10 was associated with 30-day negative outcomes.

Keywords
Generalized anxiety disorder · Chronic obstructive pulmonary disease · COPD exacerbation · Emergency department · GAD-7

Introduction

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by persistent respiratory symptoms and limited airflow, usually caused by exposure to harmful particles or gases [1]. COPD is one of the three leading causes of death around the world and the condition often progresses with exacerbations. Exacerbation of COPD, a major reason these patients are admitted to emergency departments (EDs), is generally defined as an acute worsening of respiratory symptoms that results in the need for additional treatment [1–3]. There are many physiological variables that must be evaluated in patients admitted to the ED with COPD exacerbation. Management of such patients usu-
ally focuses on improving dyspnea with respiratory therapies and bronchodilators, treatment of concurrent infections, and measures for other comorbidities [4]. Previous studies have shown that anxiety, like other comorbidities, may play a role in the development of a COPD exacerbation and can have a negative impact on patients’ prognoses [5–8]. The prevalence of clinical anxiety ranges from 10–55% among hospitalized patients and 13–46% in outpatients [9]. It has also been reported that COPD patients are 85% more likely to develop anxiety disorders compared to healthy individuals [6].

In the stable period of COPD, it is recommended that many tools be used to measure anxiety levels in patients. Instruments such as the Hospital Anxiety and Depression Scale (HADS), the Beck Anxiety Inventory (BAI), the Anxiety Inventory for respiratory disease (AIR) score, and the Generalized Anxiety Disorder-7 (GAD-7) scale have been used to screen COPD patients for anxiety [10–12]. The GAD-7 scale is a validated tool that could be practical for assessing anxiety in COPD patients in the ED [13, 14]. Considering that patients with COPD exacerbation arrive in EDs in relatively poor clinical condition, it is thought that anxiety might be an underrecognized comorbidity in this population. There is no study in which anxiety concurrent with COPD exacerbation was evaluated in an ED setting with an easy-to-use scale such as the GAD-7. The primary aim of the current study was to estimate anxiety levels of patients using GAD-7 scale and to investigate the effects of anxiety on specific outcomes, including ED revisits, admission to the intensive care unit (ICU), and mortality.

Methods

Study design and setting

This prospective, cross-sectional study was conducted with patients presenting with acute exacerbation of COPD in the ED of a university hospital between July 2019 and January 2021. Institutional review board approval was obtained prior to study initiation and eligible patients gave informed consent to be included in the study.

Participant selection

All adult patients admitted to the ED with COPD exacerbation were consecutively included in the study. The patients who had a Glasgow Coma Scale (GCS) score <15, and those who had been diagnosed with anxiety, depression, psychosis, or neurosis by a psychiatrist within the preceding month, or had been using of neuropsychiatric medication were excluded from the study. COPD exacerbation was defined as “worsening of respiratory symptoms resulting in the need for additional treatment” based on the guidelines developed by the Global Initiative for Chronic Obstructive Lung Disease [1].

Study protocol

Patients admitted to the ED with dyspnea were evaluated by treating physicians. Patients diagnosed with COPD exacerbation were identified at this stage, and treatment for such symptoms was started immediately. Patients received standardized treatment according to current guidelines, including respiratory support, inhaled bronchodilators, and systemic corticosteroids. After the first bronchodilator treatment was completed, the patients were informed regarding the study and informed consent was obtained from those who agreed to participate.

Patients’ demographic, clinical, and laboratory characteristics were recorded on a standardized data collection form. The principal investigator evaluated each patient using the GAD-7 anxiety score once their first bronchodilator treatment was completed.

The GAD-7 scale consists of seven questions, each of which has four possible answers. On the GAD-7, a score of 10 or greater—which is defined as clinically significant anxiety [13]—is a suggested cut-off point for identifying individuals who should be evaluated by a mental health professional. After determining the GAD-7 score and initial clinical management, patients were followed up in the ED, hospitalized or discharged from the ED according to current guidelines. The study investigators did not intervene in or contribute to the patients’ diagnoses, treatments, or decisions regarding hospitalization.

Outcome measures

The primary outcome of the study was the composite endpoint of recurrent ED visits, intensive care unit (ICU) admissions, and mortality within 30 days. The patients were telephoned 30 days after being discharged from the ED. Patients who experienced one or more of these outcomes were included in the negative outcome group; those who did not experience any of these outcomes were included in the positive outcome group.

Statistical analysis

The data gathered were analyzed using SPSS Statistics for Windows v. 15.0 (IBM, Armonk, NY, USA). The Kolmogorov–Smirnov test was used to test for the normal distribution of continuous variables. Normally distributed continuous variables were tested using the student’s t-test and expressed as means and standard deviations. Continuous variables that did not fit the normal distribution were tested using the Mann–Whitney U test and expressed as medians and interquartile ranges (IQRs). The χ2 and Fisher’s exact test were used to analyze categorical variables, and data were expressed as numbers and percentages. Spearman’s rank correlation coefficient was used for the correlation analysis. The vassarstats.net website was used for the sensitivity and specificity calculations, and the data were presented with 95% confidence intervals (CIs). A P value <0.05 was considered statistically significant.

Results

A total of 92 patients with a COPD exacerbation were assessed for eligibility; 80 were included in the study after the exclusion criteria were implemented (Fig. 1). At the end of the 30-day follow-up period, 43 (53.8%) patients were in the positive outcome group and 37 (46.3%) were in the negative outcome group in terms of mortality, ICU admission, and return visits to the ED. Of the 37 patients in the negative outcome group, 33 had revisited the ED, 7 had been admitted to the ICU, and 3 had died within 30 days of initial ED admission.
Patients assessed for eligibility  
\( n=92 \)

Excluded (\( n=12 \))
- Patients with a Glasgow Coma Scale score of less than 15 (\( n=2 \))
- Patients who have been using drugs with the diagnosis of psychosis or neurosis in the last month (\( n=8 \))
- Patients who did not agree to participate in the study (\( n=2 \))

Analyzed  
\( n=80 \)

Good outcome  
\( n=43 \)
Worse outcome  
\( n=37 \)
Mortality, \( n=3 \)

Fig. 1  Patient flow chart

There were no significant differences in demographic and clinical characteristics between the negative and positive outcome groups (\( \textbf{Table 1} \)). Also, initial laboratory test results, including arterial blood gas, complete blood count, C-reactive protein levels, were similar between the groups (\( \textbf{Table 2} \)).

The median GAD-7 score of all patients was 7 (IQR 4–11). The positive outcome group had a median score of 6 (IQR 2–8), while the negative outcome group had a median score of 7 (IQR 4–13). There was a weak correlation between number of ED revisits each patient had and GAD-7 score (\( r = 0.230, P = 0.040 \)).

Patients who had a GAD-7 score >10 were defined as having clinically significant anxiety and were analyzed separately. A total of 25 patients were included in this subgroup: 9 patients (20.9%) were in the positive and 16 (43.2%) patients were in the negative outcome group. The GAD-7 scores of patients with negative outcomes were significantly higher than those of patients with positive outcomes (\( P = 0.032 \)).

The performance of GAD-7 scores in predicting negative outcomes was evaluated. For a threshold GAD-7 score of 10, a sensitivity of 43.2%, specificity of...
79.1%, positive likelihood ratio of 2.1, and negative likelihood ratio of 0.7 were determined. The distribution of the patients according to their GAD-7 scores is presented in Fig. 2.

Discussion

Patients experiencing COPD exacerbation usually arrive at the ED in poor clinical condition, and therefore concurrent psychiatric comorbidities might be underrecognized. In this study, we found that an easy-to-use screening tool could predict various adverse outcomes and identify patients who might benefit from psychiatric support in the ED setting. Especially in patients with clinically significant anxiety, intervening at this stage could improve patient outcomes.

Many studies have confirmed a relationship between COPD and anxiety. A systematic review of 24 articles revealed that anxiety and depression are common comorbid conditions in patients hospitalized for COPD [15]. According to a prospective cohort study, COPD was associated with a greater risk of anxiety (odds ratio [OR] 1.85; 95% CI 1.07–3.18) compared to matched controls. In the same study, anxiety was found to be related to poorer health outcomes, including worse submaximal exercise performance and a greater risk of self-reported functional limitations (OR 2.41; 95% CI 1.71–3.41) [6]. COPD patients are also approximately 10 times more likely to experience panic disorder or panic attacks than healthy individuals [16]. However, all these studies were conducted on stable COPD patients. No study that evaluated the anxiety of COPD patients experiencing exacerbated symptoms who were assessed using a valid tool was found in the literature.

Data reported in the literature concerning the diagnosis of anxiety in COPD patients varies, and it is therefore not possible to clearly determine the frequency of the condition in this cohort. The main reason for this is that a wide variety of diagnostic tools are used to diagnose anxiety. In a multicenter study, Baker et al. compared the test performance characteristics of three anxiety screening questionnaires used for COPD patients [12]. Using the Mini-International Neuropsychiatric Interview as the gold standard, they found that the area under the curve values of the three anxiety scores were 0.78 (95% CI 0.69–0.87) for GAD-7, 0.74 (95% CI 0.64–0.84) for AIR, and 0.66 (95% CI 0.56–0.76) for HADS-A, and 0.66 (95% CI 0.56–0.76) for HADS-A, respectively [12]. The area under the curve value of the GAD-7 was significantly higher than the AIR score. In our study, we preferred to use the GAD-7 score because of its stronger diagnostic performance and its ease of application in the ED setting.

Delayed diagnosis of anxiety in COPD patients is associated with many barriers caused by patients, physicians, and the healthcare system [17]. Using standardized diagnostic criteria or screening instruments may facilitate the diagnosis and referral of patients. As Spitzer et al. revealed, higher scores on the GAD-7 scale are an excellent measure of severity, as evidenced by the fact that they are strongly associated with multiple functional impairments and an increased number of disability days [13]. In this study, a GAD-7 score was recorded for all patients who scored over 4 (29 of the patients with positive outcomes and

### Table 1 Baseline characteristics of the study population

| Positive outcome | Negative outcome | P value |
|------------------|------------------|---------|
| Age * | 67 ± 11 | 70 ± 9 | 0.175 |
| Male sex, n (%) | 36 (83.7%) | 34 (91.9%) | 0.326 |
| Diabetes mellitus, n (%) | 13 (30.2%) | 12 (32.4%) | 0.832 |
| Hypertension, n (%) | 18 (41.9%) | 18 (48.6%) | 0.543 |
| Chronic renal disease, n (%) | 6 (14.0%) | 2 (5.4%) | 0.275 |
| History of stroke, n (%) | 2 (4.7%) | 1 (2.7%) | 1.000 |
| Congestive heart failure, n (%) | 10 (23.3%) | 10 (27.0%) | 0.368 |
| Active smoking, n (%) | 12 (27.9%) | 8 (21.6%) | 0.517 |

### Table 2 Laboratory evaluation of chronic obstructive lung disease (COPD) exacerbation regarding outcome

| Positive outcome | Negative outcome | P value |
|------------------|------------------|---------|
| pH | 7.40 ± 0.05 | 7.40 ± 0.06 | 0.674 |
| pO2 (mm Hg) | 52 ± 23 | 54 ± 24 | 0.817 |
| pCO2 (mm Hg) | 42 ± 9 | 40 ± 11 | 0.370 |
| HCO3 (mmol/L) | 26 ± 4 | 25 ± 4 | 0.380 |
| Lactate (mg/dL) | 16.7 ± 7.0 | 19.4 ± 13.5 | 0.279 |
| O2 saturation (%) | 90 ± 12 | 89 ± 9 | 0.708 |
| Hemoglobin (g/dL) | 12.9 ± 2.2 | 13.0 ± 2.4 | 0.899 |
| Leukocyte count (cells × 10^3/μL) * | 9.7 (7.6–12.7) | 12.0 (9.1–15.7) | 0.365 |
| C-reactive protein (mg/dL) * | 39 (9–104) | 16 (7–77) | 0.189 |

* Mean ± SD Mean ± standard deviation, Mean (IQR) Median (interquartile range)
36 der Patienten mit negativen Ergebnissen. Neun von den 29 Patienten (31%) mit positiven Ergebnissen wurden zu erleben, dass klinisch signifikante Angst (GAD-7 Score > 10), verglichen mit 26 von den 36 Patienten (62%) mit negativen Ergebnissen. Obwohl Angst nicht direkt mit Mortalität verknüpft ist, berücksichtigt die Tatsache, dass eine negative Ausbeute in unserer Überprüfung auf die ED, ist es möglich, dass es eine Beziehung zwischen Angst und wiederholter COPD-Exazerbation gibt.

Viele Faktoren können Einfluss auf die Rehospitalisierung haben, bei Patienten mit COPD-Exazerbation und verbinden die Risikofaktoren [18]. Sie fanden keine signifikante Korrelation zwischen einer 1-Jahres-Exazerbation und Angstsymptome, die in 41% der beobachteten Patienten vorkamen [18]. Jedoch, von 406 konsekutiven Patienten hospitalisierten für akute COPD-Exazerbationen, die mit schwerer Gesundheit (wie beobachtet durch das St. George’s Respiratory Questionnaire) und mehr schweren Angstsymptomen (aber nicht mehr depressive Symptome) hatten eine 1,36-mal höhere Exazerbationsrate im Vergleich zu jenen, die keine Angst (score < 8) hatten [10]. Als dieser Studie ausgewertet wurden, dass Patienten mit COPD-Exazerbation in Akutversorgung waren, war es nicht möglich, die dauerhafte Wirkung von Angst und ihre Beziehung zu der Exazerbationsdauer zu ermitteln.

Limitationen

Unsere Studie hat einige Limitationen. Zunächst, es wurde in einer Einrichtung durchgeführt, mit einer kleinen Stichprobe, die die Generalisierbarkeit der Ergebnisse einschränkt. Zweitens, die Beobachtung bei Patienten mit COPD-Exazerbation, die in der Intensivstation behandelt wurden, wurde nicht möglich. Letztendlich, obwohl wir die GAD-7-Skala zu nutzen, um Angst nachzuweisen, fanden wir für die Vorhersage eines negativen Ergebnisses durch die GAD-7 Score eine Sensitivität von 43,2%, eine Spezifität von 79,1%, eine positive Likelihood-Ratio von 2,1 und eine negative Likelihood-Ratio von 0,7 ermittelt.

Schlussfolgerung: Bei Patienten in der Notaufnahme mit COPD-Exazerbation steht ein GAD-7-Score von ≥ 10 mit negativen Ergebnissen innerhalb von 30 Tagen in Zusammenhang.

Schlüsselwörter

Generalisierte Angststörung · Chronisch obstruktive Pulmonale Erkrankung · COLD-Exazerbation · Notfallabteilung · GAD-7

Zusammenhang zwischen klinischer Angst und Ergebnissen bei Patienten mit Exazerbation chronisch obstruktiver Lungenerkrankung in der Notaufnahme

Ziel: Angst ist eine Komorbidität, die in der Notaufnahme nicht routinemäßig bei Patienten mit Exazerbation einer chronisch obstruktiven Lungenerkrankung (COPD) erfasst wird. Angst bei Patienten mit COPD-Exazerbation kann mit einem negativen Verlauf einhergehen. Der Generalized Anxiety Disorder 7 (GAD-7) Score ist ein einfaches, zu benutzendes Instrument, um Angst festzustellen. Die vorliegende Studie hatte das Ziel, den Zusammenhang zwischen dem GAD-7-Score und den Ergebnissen bei Patienten mit COPD-Exazerbation in der Notaufnahme zu untersuchen.

Methoden: Eine prospektive Querschnittsstudie wurde in einer Notfallaufnahme eines akademischen Lehrkrankenhauses der Tertiärversorgung zwischen Juli 2019 und Januar 2021 durchgeführt. Darin einbezogen wurden Patienten in der Notaufnahme mit COPD-Exazerbation. Ein GAD-7-Score von ≥ 10 wurde als klinisch bedeutsame Angst definiert. Negative Ergebnisse wurden definiert als zusammengesetzter Endpunkt aus Wiedervorstellung in der Notaufnahme, Aufnahme auf die Intensivstation und Mortalität. Es wurde der Zusammenhang zwischen klinisch bedeutsamer Angst und negativen Ergebnissen innerhalb von 30 Tagen ermittelt.

Ergebnisse: Insgesamt wurden 92 Patienten hinsichtlich ihrer Eignung beurteilt, und 80 wurden in die Studie aufgenommen. Negative Ergebnisse gab es bei 37 Patienten (46,3%). Zwar wurde kein signifikanter Unterschied bei den medianen GAD-7-Scores zwischen Patienten mit positiven und negativen Ergebnissen festgestellt, aber die negativen Ergebnisse waren signifikant höher bei Patienten mit einem GAD-7-Score von ≥ 10 (n = 25; p = 0,03). Für die Vorhersage eines negativen Ergebnisses durch den GAD-7-Score wurden eine Sensitivität von 43,2%, eine Spezifität von 79,1%, eine positive Likelihood-Ratio von 2,1 und eine negative Likelihood-Ratio von 0,7 ermittelt.

Conclusions

Patienten mit COPD-Exazerbationen erleben multiple Komorbiditäten und frequent ED Visits. Early recognition and treatment of all comorbidities in these patients is essential to reduce the frequency of exacerbation episodes. Anxiety is a comorbidity that is not routinely addressed in the ED setting in this patient group. The GAD-7 anxiety score is a tool that can provide a guide to the ED to predict negative outcomes.
**Funding.** There is no funding to declare for this study.

**Author Contribution.** FY and NOD contributed to conception; FY, NOD, EY, SY, İUO and MP contributed to design; NOD contributed to supervision; FY, contributed to data collection and processing; FY and NOD, contributed to analysis and interpretation; FY and İUO contributed to literature review; FY, NOD, EY, SY and İUO contributed to writing; DK, NOD, EY, SY, İUO and MP contributed to critical review.

**Declarations**

**Conflict of interest.** M.F. Yaldizkaya, N.Ö. Doğan, İ.U. Özтурان, E. Yaka, S. Yılmaz and M. Pekdemir declare that they have no competing interests.

Institutional review board approval was obtained for the study (KÜ GÖAEEK- 2019/11.06, project no.: 2019/209). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Consent to participate: Volunteers gave written informed consent before study enrollment.

**References**

1. Global Initiative for Prevention, Diagnosis and Management of Chronic Obstructive Lung Disease (2021) GOLD reports. https://goldcopd.org/2021-gold-reports/. Accessed 10 Oct 2021
2. World Health Organization (2020) The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 10 Oct 2021
3. GBD 2019 Diseases and Injuries Collaborators (2019) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study. Lancet 2020(396):1204–1222
4. Wedzicha JA, Seemungal TA (2007) COPD exacerbations: defining their cause and prevention. Lancet 370:786–796
5. Laurin C, Moullec G, Bacon SL, Lavoie KL (2012) Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med 185:918–923
6. Eisner MD, Blanc PD, Yelin EH, Katz PP, Sanchez G, Iribarren C et al (2010) Influence of anxiety on health outcomes in COPD. Thorax 65:229–234
7. Yohannes AM, Kaplan A, Hanania NA (2018) Anxiety and depression in chronic obstructive pulmonary disease: recognition and management. Cleve Clin J Med 85(2 Suppl 1):S11–S18
8. Panagioti M, Scott C, Blakemore A, Coventry PA (2014) Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 9:1289–1306
9. Willgoss TG, Yohannes AM (2013) Anxiety disorders in patients with COPD: a systematic review. Respir Care 58:858–866
10. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW et al (2008) Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 178:913–920
11. de Godoy DV, de Godoy RF (2003) A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. Arch Phys Med Rehabil 84:1154–1157
12. Baker AM, Holbrook JT, Yohannes AM, Eakin MN, Sugar EA, Henderson RJ et al (2018) American Lung Association airways clinical research centers. Test performance characteristics of the AIR, GAD-7, and HADS-anxiety screening questionnaires for anxiety in chronic obstructive pulmonary disease. Ann Am Thorac Soc 15:926–934
13. Spitzer RL, Kroenke K, Williams JB, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097
14. Ruiz MA, Zamorano E, García-Campayo J, Pardo A, Freire O, Rejas J (2011) Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord 128:277–286
15. Pooler A, Beech R (2014) Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chron Obstruct Pulmon Dis 9:315–330
16. Livermore N, Sharpe L, McKenzie D (2010) Panic attacks and panic disorder in chronic obstructive pulmonary disease: a cognitive behavioral perspective. Respir Med 104:1246–1253
17. Maurer J, Rebapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM et al (2008) Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 134(4 Suppl):43S–56S
18. Gudmundsson G, Gislason T, Janson C, Lindberg E, Hallin R, Ulrik CS et al (2005) Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 26:414–419